Program
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492
Its studies are mostly in Lupus Erythematosus, Systemic, led by AstraZeneca.
Furthest: phase 2, since Jul 29, 20242 company-led studies, 2 open or runningNext primary completion: May 5, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 22 open or running | phase 2since Jul 29, 2024 | Jul 29, 2024 | May 5, 2027phase 1 · NCT06916806 |
- Named in AstraZeneca’s own pipeline as
AZD5492
, phase 1, as of Oct 30, 2026 (source).
Also a collaborator on its studies: Fortrea.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 29, 2024First study: phase 2 study in RecurrenceFirst studyNCT06542250 · 174 planned · United States, Australia, Canada and more
- Mar 13, 2025Phase 1 study in Lupus Erythematosus, SystemicNCT06916806 · 72 planned · United States, Canada, China and more
Ahead
- May 5, 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT06916806
- Dec 18, 2029Primary completion: phase 2 study in RecurrenceNCT06542250
TargetBeta
“A trispecific immunoglobulin G (IgG)-like T-cell engaging (TCE) antibody targeting the tumor-associated antigen (TAA) CD20 and the T-cell surface antigens CD3 and CD8, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD20/anti-CD3/anti-CD8 trispecific anti…”NCIt, read by Claude
“A trispecific immunoglobulin G (IgG)-like T-cell engaging (TCE) antibody targeting the tumor-associated antigen (TAA) CD20 and the T-cell surface antigens CD3 and CD8, ”NCIt, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06916806Lupus Erythematosus, Systemic · United States, Canada, China and more | 1 | Recruiting | May 5, 2027 | 72 |
| NCT06542250Recurrence · United States, Australia, Canada and more | 2 | Recruiting | Dec 18, 2029 | 174 |
How it is read
Names in the registry
- “AZD5492”, 2 entries
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.